Highest-scoring questions on the site.
The case in front of me: PIONEER-4 · 2 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
The case in front of me: nausea · tirzepatide · SURMOUNT-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
The case in front of me: SUSTAIN-6 · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if…
The case in front of me: 95.2% · VendorInvestigate · 97.9%. I have two candidate explanations and no way to distinguish them. The same procedure has worked without…
Stated plainly: minus 80 °C · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the source. I…
What I am working with: ALT · mazdutide. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My background is…
This came up because two published schedules for the same agent differ. I would like help reading this properly rather than being told what conclusion to reach. I…
I am reading the trial table rather than the press release, which is why the numbers differ. I want to understand what this actually establishes, as opposed to what…
Setup, so nobody has to ask: 95.2% · Medutest · 96.8% · Janoshik. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I…
I am comparing a supplier certificate against an independent result on the same lot. The empirical answer seems settled. The explanation does not. If the honest…
The lot number on the vial matches the certificate, which at least rules out the easy problem. I keep seeing this stated as a fact with no explanation attached, and…
Concretely: ferritin · oral semaglutide. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write…
Details up front: 30 mg · sixteen weeks · reflux. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know…
The case in front of me: Homopeptide · Wuhan Wansheng Biotechnology. I would like the axes of comparison first and the recommendation second. I have tried the first…
Stated plainly: Medutest · Xi’an Mokemei Biotechnology. I have read the primary source rather than the summary, which has left me with more questions. I understand…
What I have: 8 mg · sixteen weeks · reflux. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
The particulars: peptide mapping · ecnoglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…
Numbers first: an HPLC purity test · retatrutide. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me…
The particulars: oral semaglutide · 10 mg/mL. I would rather understand the derivation than memorise the outcome. Two people I asked gave two answers that differ by a…
Conditions: a 0.5 mL insulin syringe · 8 mg · 4 mg/mL. I want the working, not the result — I need to be able to redo it with different numbers. I care about the…
The case in front of me: 99.1% · a C4 column · retatrutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…
The case in front of me: magnesium · liraglutide. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I…
Details up front: dizziness · orforglipron · SURPASS-3. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
What I am working with: minus 20 °C · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the…